Pricing Log in Create free account

AC Immune (ACIU) vs Sol-Gel Technologies Ltd. (SLGL)

AC Immune and Sol-Gel Technologies Ltd. are both Biotechnology companies. AC Immune is the larger, with a market value of $227.0M against $199.8M — 1.1× the size. AC Immune grew revenue faster over the last twelve months: −78.6% against −92.5%. Sol-Gel Technologies Ltd. has the higher net margin (−910.1% vs −962.2%) and the lower return on invested capital (−6,630.2% vs 0.00%). Across the 16 metrics below, AC Immune leads on 8 and Sol-Gel Technologies Ltd. on 8.

Valuation

Metric ACIU SLGL Biotechnology median
P/E n/m n/m 10.60
P/S 21.29 111.18 9.40
P/B 4.52 4.15 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 9.06 120.87 9.02
Earnings yield (32.74%) (9.24%) (32.88%)
Free cash flow yield (55.75%) (10.66%) (23.13%)

Profitability

Metric ACIU SLGL Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin (986.55%) (986.96%) 0.00%
Net margin (962.17%) (910.14%) 0.00%
Free cash flow margin 0.00% (1,185.18%) 0.00%
Return on equity (122.01%) (40.85%) (51.96%)
Return on assets (33.75%) (35.11%) (46.06%)
Return on invested capital 0.00% (6,630.24%) 0.00%

Growth

Metric ACIU SLGL Biotechnology median
Revenue growth (TTM) (78.60%) (92.50%) 6.76%
EPS growth (last fiscal year) (44.83%) 42.37% 29.88%
Revenue growth, 5-year CAGR (47.84%) 17.19% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACIU SLGL Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.85 10.37 4.97
Net debt to EBITDA 1.37 3.23 1.01

Dividend

Metric ACIU SLGL Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ACIU SLGL Biotechnology median
Market cap 226.96m 199.75m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack